ArticleNPJ precision oncology2026

A Phase II study of SHR-A1921, a TROP2-targeted antibody-drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma.

Guang-Liang Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.